RxDoctor Payments Data

Billy Yung, MD

Neurology · White Plains, NYNPI 1710136437

Payments from drug & device makers

$306in general payments, 2019–2025

Across 6 payments — averaging $50.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$112
  • Biogen$97
  • Lundbeck LLC$36
  • Bristol Myers Squibb$29
  • Inspire Medical Systems, Inc.$19
  • EMD Serono, Inc.$13

What the payments were for

  • Food & beverage$29296%
  • Education$134%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$306 in reported general payments places this provider in the 30th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$184,035
Medicare patients
449
Services billed
7,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin11$113,663
OnfiClobazam12$31,683
XcopriCenobamate13$30,150
Aimovig AutoinjectorErenumab-Aooe15$22,506
UbrelvyUbrogepant16$17,854
Ajovy AutoinjectorFremanezumab-Vfrm15$17,350
Dalfampridine ErDalfampridine14$16,105
Memantine Hcl ErMemantine Hcl120$12,252
Lamotrigine ErLamotrigine21$10,727
TegretolCarbamazepine18$9,473
Emgality PenGalcanezumab-Gnlm12$8,001
Lacosamide62$7,380
BelsomraSuvorexant12$5,616
Levetiracetam137$5,432
Propranolol Hcl ErPropranolol Hcl81$5,273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$13$113,66311 claims
Lundbeck LLCOnfi$36$31,68312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,623 neurology providers in New York.

Other neurology in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →